News

More than half of girls with central precocious puberty have abnormal findings on magnetic resonance imaging of the brain, report researchers.

A small number of clinical predictors and blood metabolites at birth may accurately predict which infants will have a BMI trajectory leading to overweight or obesity, a study suggests.

A study of preterm boys shows increased androgen levels at the estimated time of birth in those with low birthweight.

Most young people treated within a paediatric gender identity development service remain committed to pursuing hormonal treatment in line with their perceived gender, research shows.

Most children and adolescents who identify as transgender or gender variant continue with hormone interventions after discharge from youth endocrine services, a study shows.

Using both height and deviation from height target during growth monitoring could improve detection of pathological growth disorders in children and avoid unnecessary clinic referrals, suggest UK researchers who found the current criteria to have low sensitivity.

Childhood-onset combined pituitary hormone deficiency occurs in around one in 16,000 children, but its diagnosis is often delayed due to nonspecific presenting symptoms, say researchers.

Researchers report a “biphasic and prolonged” minipuberty in girls, and provide reference ranges for reproductive hormones during the first year of life.

Non-autosomal dominant inheritance and the presence of structural collagen defects are associated with reduced benefit of treatment with zoledronic acid in children with osteogenesis imperfecta, researchers report.

A systematic review and meta-analysis confirms a high rate of reversal of idiopathic growth hormone deficiency, albeit strongly dependent on the peak GH cutoff used.

Dutch researchers have identified key logistic failures that may lead to adolescents with endocrine disorders failing to transition successfully from paediatric to adult tertiary care.

Children with X-linked hypophosphatemia derive similar benefits from burosumab regardless of whether they start treatment before or after the age of 5 years, shows a post-hoc analysis of a randomised trial.